At-a-Glance:
| Company |
Hzymes Biotechnology Co., Ltd. |
|---|
| Specialties |
High-quality enzymes and raw materials for biomedicine, in vitro diagnostics (IVD), and mRNA vaccine/drug development |
|---|
| Mission |
Innovative underlying technology, Benefiting life |
|---|
| Noteworthy |
Only Chinese company with five major enzyme technology platforms |
|---|
| Location |
Wuhan, China |
|---|
Hzymes Biotechnology Co., Ltd. has quickly become an industry leader in the innovation, development, and large-scale manufacturing of core enzyme raw materials—not just in China, but globally. While the company’s origins in Wuhan are a point of pride, what really sets Hzymes apart is its values, which emphasize putting the customer first, fostering innovation, striving for excellence, acting with responsibility, and seeking win-win outcomes for all stakeholders.
The company’s mission is clear: “Innovative underlying technology, Benefiting life.” This mission is more than just a slogan. It’s the guiding principle behind every decision Hzymes makes, from research and development to business partnerships. Their vision is to “become a global leader in core technologies powering the bio-industry,” a goal that’s echoed in their daily operations and long-term strategy.
Since its founding in 2015, Hzymes has believed that the best breakthroughs happen when great minds work together. That philosophy is woven into the company’s DNA. Hzymes has developed five major technology platforms for enzyme creation, which form the foundation for its work with a wide range of partners.
One of the company’s greatest strengths is its ability to forge strong, mutually beneficial relationships. Hzymes doesn’t just supply enzymes—it works hand-in-hand with its partners to develop new solutions, improve processes, and tackle some of the toughest challenges in diagnostics and therapeutics. Hzymes works with over 100 IVD reagent manufacturers and maintains strategic collaborations with both domestic and international partners in the biotech and pharmaceutical sectors, including Sinovac, GenSci, Henlius Mabwell, Kingfriend, and many more. These collaborations often go far beyond simple transactions. They involve joint research projects, technology sharing, and the co-development of innovative products.
Hzymes’ international presence is also hard to miss. The company is a regular participant at major industry events, where it not only showcases its latest products but also connects with new and existing partners. For example, at the ESCMID Global Congress in Vienna in 2025, Hzymes presented its latest enzyme-based solutions for molecular diagnostics and pathogen detection.
One of the most exciting areas where Hzymes is making a mark is in the field of mRNA therapeutics and vaccines. At VIF World 2025 in Shanghai, the company introduced its comprehensive suite of mRNA solutions, including services for mRNA antigen synthesis, process development, and lipid nanoparticle (LNP) encapsulation. These offerings are the result of ongoing collaborations with universities, biotech startups, and established pharmaceutical companies.
A standout achievement in recent years has been the rapid advancement of its T7 RNA polymerase technology, a cornerstone enzyme for mRNA drug synthesis. Recognizing early on that standard wild-type T7 RNA polymerase lagged behind international competitors, Hzymes took a strategic approach—working closely with key partners like LOTUSLAKE BIOMEDICAL, Haichang Biotech, and WALVAX to implement tailored technical solutions and accelerate product improvement. Within just six months, Hzymes developed a next-generation M6 mutant T7 RNA polymerase, dramatically boosting enzyme performance.
With major R&D and production facilities in Wuhan, Shanghai, Suzhou, and Qingdao, Hzymes is able to deliver high-quality products and support to customers and partners around the world. This infrastructure means that partners can count on reliable supply and fast response times, no matter where they’re located.
What really stands out about Hzymes, though, is its collaborative spirit. The company is always open to customizing its products and services to meet the unique needs of its partners. Whether it’s developing a new diagnostic assay, scaling up vaccine production, or improving the sensitivity of PCR tests, Hzymes approaches every project as a true collaboration.
In the end, Hzymes Biotechnology’s story is one of partnership and shared ambition. By building strong relationships across the globe and staying open to new ideas and opportunities, Hzymes has positioned itself as a trusted collaborator in the world of enzyme technology and beyond. It’s a company that understands the power of working together—and that’s what makes it such a vital player in the future of biotechnology.